Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MEDRx/DWTI Make 4th Attempt to Seek US Nod for Lidocaine Patch
MEDRx said on March 25 that a new drug application has been filed with the US FDA for MRX-5LBT (Lydolyte), a lidocaine patch being developed jointly with D. Western Therapeutics Institute for the treatment of post-herpetic neuralgia. This marks the…
To read the full story
Related Article
- MEDRx/DWTI Clinch US FDA Approval for Lidocaine Patch
September 26, 2025
- FDA Snubs MEDRx/DWTI’s Lidocaine Patch Yet Again
July 16, 2024
- FDA Gives Thumbs-Down for MEDRx/DWTI’s Lidocaine Patch
October 3, 2023
BUSINESS
- Nipro’s Generic Radicut Gains ALS Nod, Aligning with Originator
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…